Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HLA class II ligandome of C1R BLCL cell line

ABSTRACT: HLA-DR, -DQ and -DP ligands from transfected C1R cells were isolated using LB3.1, SPVL3 and B721 antibodies respectively.

INSTRUMENT(S): TripleTOF 5600, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Suspension Culture

SUBMITTER: Sri Ramarathinam

LAB HEAD: Anthony Purcell

PROVIDER: PXD025877 | Pride | 2021-08-18

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DPrep1_A1112.mgf	Mgf
	DPrep1_A1112.wiff	Wiff
	DPrep1_A1112.wiff.scan	Wiff
	DPrep1_A1314.mgf	Mgf
	DPrep1_A1314.wiff	Wiff

Items per page:

1 - 5 of 552

Publications

HLA class II immunopeptidomics reveals that co-inherited HLA-allotypes within an extended haplotype can improve proteome coverage for immunosurveillance.

Ramarathinam Sri H SH Ho Bosco K BK Dudek Nadine L NL Purcell Anthony W AW

Proteomics 20210817 17-18

Human leucocyte antigen (HLA) class II molecules in humans are encoded by three different loci, HLA-DR, -DQ, and -DP. These molecules share approximately 70% sequence similarity and all present peptide ligands to circulating T cells. While the peptide repertoires of numerous HLA-DR, -DQ, and -DP allotypes have been examined, there have been few reports on the combined repertoire of these co-inherited molecules expressed in a single cell as an extended HLA haplotype. Here we describe the endogeno ...[more]

PMID: 34357683

Similar Datasets

HLA class II ligandome from HOM-2 and JY cell lines (HLA-DR an HLA-DP ligands)

Project description:A high-throughput mass spectrometry analysis was used to identify more than 16,000 cell peptides bound to several HLA-DR and -DP class II molecules isolated from large amounts of two human cell lines (HOM-2 and JY).

2021-11-03 | PXD028006 | Pride

HLA-II HOM2 and JY

Project description:49633 -> HOM2 HLA-DR 49637 -> HOM2 HLA-DP 49647 -> JY HLA-DR 49649 -> JY HLA-DP

2018-07-31 | MSV000082670 | MassIVE

Sampling from proteome to HLA-DR ligandome

Project description:Comprehensive analysis of the complex nature of the Human Leukocyte Antigen (HLA) class II ligandome is of utmost importance to understand the basis for CD4+ T cell mediated immunity and tolerance. Here, we implemented important improvements in the analysis of the repertoire of HLA-DR-presented peptides, using hybrid mass spectrometry-based peptide fragmentation techniques on a ligandome sample isolated from matured human monocyte-derived dendritic cells (DC). The reported data set constitutes nearly 14 thousand unique high-confident peptides, i.e. the largest single inventory of human DC derived HLA-DR ligands to date. From a technical viewpoint the most prominent finding is that no single peptide fragmentation technique could elucidate the majority of HLA-DR ligands, due to the wide range of physical chemical properties displayed by the HLA-DR ligandome. Our in-depth profiling allowed us to reveal a strikingly modest correlation between the abundance levels of surface-presented peptides and the cellular expression of their source proteins. Important selective sieving from the sampled proteome to the ligandome, was evidenced by specificity in the sequences of the core regions both at their N- and C- termini, hence not only reflecting binding motifs but also dominant protease activity associated to the endolysosomal compartments. Moreover, we demonstrate that the HLA-DR ligandome reflects a surface representation of cell-compartments specific for biological events linked to the maturation of monocytes into antigen presenting cells. Our results present new perspectives into the complex nature of the HLA class II system and will aid future immunological studies in characterizing the full breadth of potential CD4+ T cell epitopes relevant in health and disease.

2016-01-25 | PXD002951 | Pride

Influenza-derived peptide presentation by HLA-A*24:02

Project description:Identification of influenza virus-derived peptides presented by Human Leukocyte Antigen (HLA) molecules of the C1R (Class I reduced) B-lymphoblastoid cell line, transfected with the HLA class I allele HLA-A*24:02, after influenza infection.

2021-04-08 | PXD020292 | Pride

Influenza-derived peptide presentation by HLA-A*11:01

Project description:Analysis of the immunopeptidome of Human Leukocyte Antigen (HLA)-A*11:01 during influenza infection. Analyses were performed using the Class I reduced C1R cell line transfected with the HLA class I allele HLA-A*11:01.

2022-02-15 | PXD028985 | Pride

Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells

Project description:Immunopeptidomic profiling of HLA-DR diverse monocyte-derived dendritic cells pulsed with SARS-CoV-2 spike (S) protein.

2021-07-09 | PXD021672 | Pride

Identification of HLA-B*57:01-restricted endogenous and HIV epitopes

Project description:A novel modified HLA-B*57:01-restricted epitope was identified in one of the reversed-phase fractions following immunoaffinity purification of HLA-peptide complexes from C1R cells expressing HIV envelope protein. Also includes six immunopeptidome datasets from several B57 and env transfected cell lysates.

2018-02-19 | PXD004471 | Pride

Impacts of HLA-B57 micropolymorphism (MRM)

Project description:Comparison of peptide ligands of major histocompatibility class (MHC) I isolated by immunoaffinity purification from the C1R (Class I reduced) B-lymphoblastoid cell line, transfected with the MHC class I alleles HLA-B*57:01, HLA-B*57:03 and HLA-B*58:01.

2018-10-24 | PXD009850 | Pride

Promiscuity of peptides presented in HLA-DP molecules from different immunogenicity groups is associated with T-cell cross-reactivity

Project description:In the context of HLA-DP-mismatched allogeneic stem cell transplantation, mismatched HLA-DP alleles can provoke profound allo-HLA-DP-specific immune responses from the donor T-cell repertoire leading to graft-versus-leukemia effect and/or graft-versus-host disease in the patient. The magnitude of allo-HLA-DP-specific immune responses has been shown to depend on the specific HLA-DP disparity between donor and patient and the immunogenicity of the mismatched HLA-DP allele(s). HLA-DP peptidome clustering (DPC) was developed to classify the HLA-DP molecules based on similarities and differences in their peptide-binding motifs. To investigate a possible categorization of HLA-DP molecules based on overlap of presented peptides, we identified and compared the peptidomes of the thirteen most frequently expressed HLA-DP molecules. Our categorization based on shared peptides was in line with the DPC classification. We found that the HLA-DP molecules within the previously defined groups DPC-1 or DPC-3 shared the largest numbers of presented peptides. However, the HLA-DP molecules in DPC-2 segregated into two subgroups based on the overlap in presented peptides. Besides overlap in presented peptides within the DPC groups, a substantial number of peptides was also found to be shared between HLA-DP molecules from different DPC groups, especially for groups DPC-1 and -2. The functional relevance of these findings was illustrated by demonstration of cross-reactivity of allo-HLA-DP-reactive T-cell clones not only against HLA-DP molecules within one DPC group, but also across different DPC groups. The promiscuity of peptides presented in various HLA-DP molecules and the cross-reactivity against different HLA-DP molecules demonstrate that these molecules cannot be strictly categorized in immunogenicity groups.

2022-02-12 | PXD030591 | Pride

Characterization of the HLA class I Ligandome from Extracellular vesicles

Project description:Extracellular vesicles have shown promise in the field of anti-tumor vaccines. EVs are antigen-presenting entities capable of eliciting potent T-cell responses and have therefore being explored as cell-free based peptide vaccine vectors. However, whether the EV ligandome sufficiently resembles the cell ligandome as to preserve antigenicity and immunogenicity of the ligands is still a crucial aspect to be addressed. In particular, when aiming to use EVs as cell-free vaccine vectors. To understand whether HLA-I complexes homing to EVs display the same ligand sequence features and characteristics than those homing to the cell surface, we used a highly sensitive MS-based immunopeptidomics approach to generate a comprehensive side-by-side analysis of the EV and whole-cell (WC) ligandomes. In this work we identified thousands of ligands derived from both EVs and WCs, which allowed a deep characterization of important ligand properties such as the occurrence of PTMs in both ligandomes. Our results indicate that EVs are as good as cells when it comes to antigen presentation, since the sequence properties of the antigens were conserved in EVs and WCs ligandomes. Interestingly, EVs were enriched in HLA-B ligands and cysteinylated peptides, which can ultimately affect the antigenicity and immunogenicity of the ligands and should be taken into consideration when developing cell-free EV-based peptide vaccination approaches.

2021-07-05 | PXD021177 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data